Skip to main content
main-content

29-09-2019 | Gynaecological cancer | Video

ESMO 2019: PAOLA-1 supports maintenance olaparib plus bevacizumab for newly diagnosed advanced ovarian cancer

Adding a PARP inhibitor to maintenance bevacizumab therapy improves progression-free survival for advanced ovarian cancer regardless of BRCA mutation status (1:41).

Funding for independent interviews at ESMO 2019 was provided in part by F.Hoffmann-La Roche Ltd, Basel, Switzerland.

See the research in context now

with trial summaries, expert opinion and congress coverage

Image Credits